RAPT Therapeutics, Inc.

NasdaqGM RAPT

RAPT Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.77

RAPT Therapeutics, Inc. EPS (Diluted) is USD -2.77 for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

RAPT Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.53, a -3.69% change year over year.
RAPT Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -2.44, a 3.94% change year over year.
RAPT Therapeutics, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -2.54, a 81.79% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGM: RAPT

RAPT Therapeutics, Inc.

CEO	Dr. Brian Russell Wong M.D., Ph.D.
IPO Date	Oct. 31, 2019
Location	United States
Headquarters	561 Eccles Avenue
Employees	70
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Key trends

Past 5 years